HAVCR2 and cancer: Among diverse cancer types, TIM‐3 overexpression was most commonly seen in pancreatic cancer (20/55, 36.4%) followed by small intestine cancer (3/12, 25%), breast cancer (12/49, 24.5%), and lung cancer (4/20, 20%; Figure 2).